Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate

American Journal of Surgical Pathology

Volumn 39, Issue 6, 2015, Pages 767-771

  Haratake, Joji ^a   Yasunaga, Chikao ^a   Ootani, Akifumi ^a   Shimajiri, Shohei ^b   Matsuyama, Atsuji ^b   Hisaoka, Masanori ^b  

^a Saiseikai Yahata General Hospital   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

dialysis; histiocytosis; lanthanum carbonate; mucosal deposition; stomach

Indexed keywords

LANTHANUM; LANTHANUM CARBONATE;

ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; CHEMISTRY; DUODENUM; FEMALE; GASTROINTESTINAL DISEASES; HISTIOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; RENAL DIALYSIS; RENAL INSUFFICIENCY;

AGED; DUODENUM; FEMALE; GASTROINTESTINAL DISEASES; HISTIOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; LANTHANUM; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 84929949168     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000385     Document Type: Article

References (17)

1. Albaaj F Hutchison AJ. Lanthanum carbonate (fosrenol): A novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. J Clin Pract.2005. 59. 1091-1096.
2. Ervo R, Dertenois LT, Ardu F, et al. Lanthanum carbonate: A postmarketing observational study of efficacy and safety. J Nephrol. 2012;25:490-496.
3. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: An updated systematic review and meta-ana lysis. Lancet. 2013;382:1268-1277.
4. Yamada S, Yoshida H, Taniguchi M, et al. Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialy sis patients. Intern Med. 2012;51:2097-2104.
5. Nakai S, Watanabe Y, Masakane I, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2011). Ther Apher Dial. 2013;17:567-611.
6. Lacour B, Lucas A, Auchère D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int. 2005;67:1062-1069.
7. Kato A, Takita T, Furuhashi M. Accumulation of lanthanum carbonate in the digestive tracts. Clin Exp Nephrol. 2010;14:100-101.
8. Cerny S, Kunzendorf U. Images in clinical medicine. Radiographic appearance of lanthanum. N Engl J Med. 2006;355:1160.
9. Muller C, Chantrel F, Faller B. A confusional state associated with use of lanthanum carbonate in a dialysis patient: A case report. Nephrol Dial Transplant. 2009;24:3245-3247.
10. Haratake J, Horie A, Takeda S. Histochemical and ultrastructural study of copper-binding protein in hepatocellular carcinoma. Cancer. 1987;60:1269-1274.
11. Voltaggio L, Lam-Himlin D, Limketkai BN, et al. Message in a bottle: Decoding medication injury patterns in the gastrointestinal tract. J Clin Pathol. 2014;67:903-912.
12. Abraham SC, Cruz-Correa M, Lee LA, et al. Alendronateassociated esophageal injury: Pathologic and endoscopic features. Mod Pathol. 1999;12:1152-1157.
13. Haig A, Driman DK. Iron-induced mucosal injury to the upper gastrointestinal tract. Histopathology. 2006;48:808-812.
14. Greenson JK , Trinidad SB, Pfeil SA, et al. Gastric mucosal calcinosis. Calcified aluminum phosphate deposits secondary to aluminum-containing antacids or sucralfate therapy in organ transplant patients. Am J Surg Pathol. 1993;17:45-50.
15. Crowder CD, Grabowski C, Inampudi S, et al. Selective internal radiation therapy-induced extrahepatic injury: An emerging cause of iatrogenic organ damage. Am J Surg Pathol. 2009;33:96 3-975.
16. Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract (GIT): A new entity associated with mucosal injury. Am J Surg Pathol. 2013;37:1686-1693.
17. Davis RL, Abraham JL. Lanthanum deposition in a dialysis patient. Nephrol Dial Transplant. 2009;24:3247-3250.